35 results on '"Morgner, Anke"'
Search Results
2. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia
3. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
4. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
5. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
6. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP
7. Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma
8. Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse
9. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
10. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia—Lessons Learned from the Prospective BRIDGE Trial
11. S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
12. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
13. 1142. Plasma with high titers of anti-SARS-Cov2 antibodies improves outcome of COVID-19 in patients with hematological malignancy and cancer in a randomized controlled trial
14. Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols
15. Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols
16. Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse
17. Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia
18. Unusual clinico-pathological features in primary Hodgkin’s lymphomas of the central nervous system
19. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
20. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
21. Real-World Analysis of Teclistamab in 115 RRMM Patients from Germany
22. Unicentric Retrospective Analysis of 130 Patients with Extramedullary Multiple Myeloma (EMM)
23. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
24. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP
25. Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases
26. Long Term Follow up and Impact of Comorbidity Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML - Lessons Learned from the Prospective Bridge Trial -
27. Primär endoskopische Versorgung oberflächlicher Urothelkarzinome des oberen Harntraktes durch Laserchirurgie und endoskopische Nachsorge
28. – Updated Results from the Bridge Trial: Long-Term Survival and Impact of Donor Availability – Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML
29. Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Relapsed Or Refractory AML – Results Of The Bridge Trial –
30. Clofarabine-Based Salvage Therapy and Conditioning Regimen in Patients with Relapsed or Refractory AML
31. Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)
32. Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory AML – Interim Results of the Bridge Trial
33. Unusual clinico-pathological features in primary Hodgkin’s lymphomas of the central nervous system
34. Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantaion - a Multicenter Retrospective Analysis
35. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.